{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"35"}],"units":"Participants"}],"groups":[{"description":"Patients received oral administration of afatinib 90mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"BG000","title":"Afatinib 90mg"},{"description":"Patients received oral administration of afatinib 120mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"BG001","title":"Afatinib 120mg"},{"description":"Patients received oral administration of afatinib 150mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"BG002","title":"Afatinib 150mg"},{"description":"Patients received oral administration of afatinib 160mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"BG003","title":"Afatinib 160mg"},{"description":"Patients received oral administration of afatinib 200mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"BG004","title":"Afatinib 200mg"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"64","upperLimit":"80","value":"65.0"},{"groupId":"BG001","lowerLimit":"50","upperLimit":"77","value":"58.0"},{"groupId":"BG002","lowerLimit":"54","upperLimit":"77","value":"65.0"},{"groupId":"BG003","lowerLimit":"45","upperLimit":"70","value":"61.0"},{"groupId":"BG004","lowerLimit":"54","upperLimit":"75","value":"62.5"},{"groupId":"BG005","lowerLimit":"45","upperLimit":"80","value":"64.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"24"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"11"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Gender","unitOfMeasure":"Participants"}],"populationDescription":"Treated set which included all patients who took at least one dose of afatinib."}